RSS

active pharmaceutical ingredients (APIs)

Small molecule company Cambrex has opened a new quality control (QC) laboratory at its site in Paullo, Milan, Italy. Read more

News

Phil Morton, chief technical officer, Albumedix discusses the effects that albumin can infer on APIs in formulations, and the proposed mechanism behind them. Read more

Opinion

Contract development and manufacturing organisation (CDMO) Particle Sciences has launched a new active pharmaceutical ingredient (API) screening programme in order to strengthen its nanomilling offering. Read more

News

The September issue of @EPM_magazine is available for download with all the regulars and features on artificial intelligence, formulation, analytical lab techniques, artificial intelligence, APIs/HPAPIs plus a serialisation supplement. Read more

Latest Issue

Manufacturer of small molecule innovator and generic active pharmaceutical ingredients (APIs), Cambrex, has completed its acquisition of dosage form contract development and manufacturing organisation (CDMO), Halo Pharma. Read more

News

Here, Jonathan Gaik, director, Natoli Scientific, looks at the critical issue of powder flow and how solving issues before production can reduce product performance issues later down the line. Read more

Opinion

Carbogen Amcis (Swiss-based pharma process development and API manufacturing company) has opened a new office located in Kyoto, Japan. Read more

News

Manufacturer of small molecule innovator and generic APIs, Cambrex, has entered into a definitive agreement to acquire Halo Pharma — a dosage form contract development and manufacturing organisation (CDMO). Read more

News

Specialty chemical solutions company, Charkit, has acquired the assets of a North American distributor of fine chemicals and custom manufactured intermediates and active pharmaceutical ingredients (APIs), ChayseChem. Read more

News

Investment-type holding company of SK Group, SK Holdings, has come to an arrangement where it will acquire 100% of the ownership interests in AMPAC Fine Chemicals (AFC) — a contract development and manufacturing organisation (CDMO). Read more

News

A report from bioLIVE has forecasted that outsourcing will play an increasing role in the bio supply chain and that continuous manufacturing, API and process analytical technology (PAT) expertise will be vital to future growth. Read more

Analysis

Here, Pingyun (P.Y.) Chen, PhD, director of Early Development at Catalent Pharma Solutions, details some of the important considerations required in product development and how a holistic approach can help save money and time in the long run. Read more

Opinion

Manufacturer of small molecule innovator and generic active pharmaceutical ingredients (APIs), Cambrex, has announced that it will expand research and development capabilities at its Milan site. Read more

News

Manufacturer of small molecule innovator and generic active pharmaceutical ingredients (APIs), Cambrex, has started a $5 million expansion of laboratory facilities at its Karlskoga site in Sweden. Read more

News

Manufacturer of small molecule innovator and generic active pharmaceutical ingredients (APIs), Cambrex, has announced the completion of its pilot plant expansion at its High Point facility in North Carolina. Read more

News

STA Pharmaceutical (WuXi STA), a subsidiary of WuXi AppTec has announced that its active pharmaceutical ingredient (API) R&D and manufacturing facility in Changzhou, China, has passed its first inspection by the US Food and Drug Administration (FDA). Read more

News

Ardena, a contract development and manufacturing organisation (CDMO), has acquired Syntagon, a contract manufacturer of novel active pharmaceutical ingredients (APIs) and excipients. Read more

News

A long-term contract extension has been agreed by Proteon Therapeutics and Lonza Pharma & Biotech for the commercial supply of the investigational vonapanitase’s active pharmaceutical ingredient (API). Read more

News

Manufacturer and supplier of controlled substance APIs, Noramco, and manufacturer and supplier of functional excipient platforms, SPI Pharma, have signed an agreement to develop and license a set of ‘value-added’ formulation packages Read more

News

Contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions, is investing £6 million in its pilot plant facility at its UK site for the enhancement of scale-up and small to midscale commercial API manufacturing capabilities. Read more

News